Phase Ib Study of Efsubaglutide Alfa Injection in Obese Adolescents

Recruiting now · Phase 1 · Has a placebo group

Conditions studied: Adolescence Obesity

In brief

This is a Phase Ib, randomized, double-blind, placebo-controlled clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of Efsubaglutide Alfa Injection following multiple-dose administration in Chinese adolescent participants with obesity.

Key facts

Study ID

NCT07693426

Run by

Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.

People needed

36

Starts

2026-07-16

Expected to finish

2027-08-31

Last updated by the study team

2026-07-30

Who can join

Age: 12 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 1. Informed consent must be obtained from the participant's parent or legally authorized representative and assent from the adolescent participant before any study-related procedures.
• 2. Adolescent participants aged ≥12 years and <18 years (at the time of informed consent).
• 3. At screening, meet the obesity criteria defined in "WS/T586-2018 Screening for Overweight and Obesity among School-age Children and Adolescents".
• 4. Before screening, have been on dietary and exercise control alone for at least 3 months with <5.0% reduction in body mass index (based on self-report or report by parent or legally authorized representative).
• 5.Must be willing to follow the diet and exercise guidance and able to maintain such stable diet and exercise lifestyle during the study period.
• 6. Female participants of childbearing potential must have a negative serum pregnancy test at screening.
• 7. Able to understand all study procedures, willing to strictly comply with the study protocol, complete the study visits as scheduled, and finish the study.

You may not qualify if…

• 1. Pre-pubertal participants (Tanner Stage I).
• 2. History of severe allergic reactions or suspected allergy to study drug or its ingredients.
• 3. Pregnant or lactating women; men or women of childbearing potential planning pregnancy or unwilling to use highly effective contraception throughout the study.
• 4. Use of weight-affecting medications before screening.
• 5. Known monogenic obesity, obesity caused by other diseases or medications,
• 6. Previously diagnosed Type 1 diabetes, Type 2 diabetes, or special types of diabetes;
• 7. history of severe hypoglycemia or recurrent symptomatic hypoglycemia (≥2 times within half a year).
• 8. Clinically significant gastric emptying abnormalities, severe chronic gastrointestinal diseases, long-term use of medications directly affecting gastrointestinal motility, or gastrointestinal surgery within 6 months prior to screening, deemed unsuitable for the study by the investigator.
• 9. History of malignancy within 5 years prior to screening, excluding clinically cured cervical intraepithelial neoplasia, squamous cell carcinoma, or basal cell carcinoma within 5 years.
• 10. Major surgery within 6 months prior to screening, or planned surgery during the study that may affect study completion or compliance;
• 11. history of bariatric surgery or planned bariatric surgery during the study (e.g., gastric bypass, gastric banding).
• 12. History of acute or chronic pancreatitis, symptomatic gallbladder disease at screening, history of pancreatic injury, or other high-risk factors for pancreatitis; or amylase or lipase >2.0×ULN at screening.
• 13. Known or suspected drug/substance abuse at screening; positive HBsAg;
• 14. Positive HCV antibody with HCV RNA above the lower limit of detection; positive HIV antibody; positive Tp-Ab.
• 15. Currently receiving or received chronic (>14 days) systemic glucocorticoid therapy within 3 months prior to screening, or evidence of severe active autoimmune disease that may require systemic glucocorticoid therapy within the next 12 months as judged by the investigator.
• 16. History of hyperthyroidism or hypothyroidism, or TSH <1.0×LLN, or TSH >1.5×ULN, or history of medullary thyroid carcinoma.
• 17. Serum calcitonin ≥50 ng/L (pg/mL) at screening; ALT >3.0×ULN, or AST >3.0×ULN, or total bilirubin >2.0×ULN; eGFR <60 mL/min/1.73 m² at screening; fasting triglycerides ≥5.64 mmol/L (500 mg/dL).
• 18. Blood donation and/or blood loss ≥400 mL or bone marrow donation within 3 months prior to screening, or presence of hemoglobinopathy, hemolytic anemia, sickle cell anemia, or hemoglobin <118 g/L (ages 12-<13 years), <129 g/L (males ≥13 years), or <114 g/L (females ≥13 years).
• 19. Participation in vaccine or medical device clinical trials within 3 months prior to screening, or any drug clinical trial within less than 3 months or 5 half-lives (whichever is longer).
• 20. History of moderate to severe depression, anxiety disorder, or severe psychiatric illness.
• 21. Any other condition that, in the opinion of the investigator, may affect the participant's safety or compliance with the study protocol.

Where it is running

• Beijing Chaoyang Hospital, Capital Medical University — Beijing, Beijing Municipality, China (enrolling)
• Qilu Second Hospital, Shandong University — Jinan, Shandong, China (enrolling)
• Wuhan Central Hospital — Wuhan, Hubei, China
• Shengjing Hospital, China Medical University — Shenyang, Liaoning, China
• Qilu Hospital, Shandong University — Jinan, Shandong, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.